These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15553363)

  • 41. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
    González-Gutiérrez JL; Gobartt AL;
    Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitor treatment in patients with delirium.
    Opdam FL; Oleksik AM; Westendorp RG
    Lancet; 2011 Mar; 377(9769):900-1; author reply 901. PubMed ID: 21397759
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.
    Logan CJ; Stewart JT
    J ECT; 2007 Mar; 23(1):28-9. PubMed ID: 17435571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.
    Alwahhabi FK
    J Psychopharmacol; 2005 Mar; 19(2):214-6. PubMed ID: 15728444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules.
    Prescrire Int; 2009 Feb; 18(99):19. PubMed ID: 19391277
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease].
    Alonso-Navarro H; Jiménez-Jiménez FJ
    Rev Neurol; 2007 May 1-15; 44(9):575-6. PubMed ID: 17492618
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of rivastigmine in a case of residual schizophrenia.
    Raguraman J; Sagar JV; Chandrasekaran R
    Can J Psychiatry; 2005 Mar; 50(4):243-4. PubMed ID: 15898469
    [No Abstract]   [Full Text] [Related]  

  • 48. Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial.
    Zaslavsky A; Haile M; Kline R; Iospa A; Frempong-Boadu A; Bekker A
    Int J Geriatr Psychiatry; 2012 Sep; 27(9):986-8. PubMed ID: 22886871
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two years' follow-up of rivastigmine treatment in Huntington disease.
    de Tommaso M; Difruscolo O; Sciruicchio V; Specchio N; Livrea P
    Clin Neuropharmacol; 2007; 30(1):43-6. PubMed ID: 17272969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication.
    Van Kernebeek MW; Ghesquiere M; Vanderbruggen N; Verhoeven E; Hubloue I; Crunelle CL
    Clin Toxicol (Phila); 2021 May; 59(5):447-448. PubMed ID: 32960128
    [No Abstract]   [Full Text] [Related]  

  • 52. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
    Kumar P; Kumar A
    Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.
    Scarzella L; Costanza A; Vastola K
    Funct Neurol; 2007; 22(2):101-4. PubMed ID: 17637213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Drug therapy of delirium in the elderly].
    Ranhoff AH
    Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3072-4. PubMed ID: 15586192
    [No Abstract]   [Full Text] [Related]  

  • 55. [Progressive supranucleair palsy: acetylcholineeserase-inhibitor a possible therapy?].
    Nijboer H; Dautzenberg PL
    Tijdschr Gerontol Geriatr; 2009 Jun; 40(3):133-7. PubMed ID: 19731749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
    Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
    [No Abstract]   [Full Text] [Related]  

  • 57. Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia.
    Bosboom JL; Stoffers D; Stam CJ; Berendse HW; Wolters ECh
    Clin Neurophysiol; 2009 May; 120(5):910-5. PubMed ID: 19386543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
    Caffarra P; Vezzadini G; Copelli S; Dieci F; Messa G; Nonis E; Venneri A
    Acta Biomed; 2007; 78(1):16-21. PubMed ID: 17687812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Grossberg GT
    Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.